Veeva Systems
VEEV
$177.47
+0.71%
Veeva Systems Inc. is the global leader in providing cloud-based software solutions specifically tailored for the life sciences industry, offering products like Veeva CRM for customer relationship management and Veeva Vault for content management. The company is a dominant, best-of-breed platform player, distinguished by its deep domain expertise and its success in displacing legacy, customized enterprise systems within its highly regulated niche. The current investor narrative is sharply focused on a significant stock price correction, which has created a debate between viewing the decline as a structural threat to its growth story or a compelling buying opportunity given its entrenched market position and long-term revenue doubling target by 2030.…
VEEV
Veeva Systems
$177.47
Related headlines
Investment Opinion: Should I buy VEEV Today?
Rating & Thesis: Hold. Veeva represents a high-quality company in a severe correction, but the risk/reward is balanced until growth re-accelerates or the technical picture stabilizes. The bullish analyst consensus and reasonable forward P/E are offset by clear growth deceleration and persistent technical weakness.
Supporting Evidence: The forward P/E of 17.08x suggests the market expects significant earnings growth, creating a valuation floor if estimates are met. Revenue growth remains healthy at 15.96% YoY, and profitability is exceptional with 74.46% gross margins and $1.39B in TTM free cash flow. However, the stock trades 45% below its 52-week high, with a relative strength of -58.20% indicating severe underperformance. The operating margin compression from 32.15% to 29.41% quarter-over-quarter raises execution concerns.
Risks & Conditions: The two biggest risks are continued growth deceleration below 15% and further multiple compression if the software sector falls out of favor. This Hold would upgrade to Buy if: 1) revenue growth re-accelerates above 18% YoY, 2) the stock establishes a technical base above $185, or 3) the forward P/E compresses below 15x. It would downgrade to Sell if: 1) revenue growth falls below 12%, 2) operating margins contract below 25%, or 3) the stock breaks below $148 support. Relative to its history and software peers, Veeva is fairly valued to slightly overvalued given its growth deceleration, trading at a premium P/S of 10.44x that requires flawless execution to justify.
Sign up to view all
VEEV 12-Month Price Forecast
Veeva presents a classic 'good company, bad stock' scenario. The underlying business is exceptional—profitable, cash-generative, and dominant in its niche—but the stock has been rightfully punished for growth deceleration and faces significant technical overhead. The forward P/E of 17x suggests the market expects earnings growth to materialize, creating asymmetric risk: upside requires growth re-acceleration, while downside is protected by the strong balance sheet and cash flow. The stance would upgrade to bullish on evidence of growth stabilization above 16% or a break above the $200 resistance level. It would turn bearish if revenue growth falls below 14% or margins contract below 27%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $230.71 and implied upside of +30.0% versus the current price.
Average Target
$230.71
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$142 - $231
Analyst target range
The stock is covered by 9 analysts, and recent institutional ratings show a mix of Buy, Overweight, and Hold/Neutral stances, with firms like Citigroup, TD Cowen, and Wells Fargo maintaining bullish ratings. The consensus leans bullish, though the absence of a specific average target price in the data prevents a precise upside calculation; the estimated revenue and EPS ranges for future periods indicate analysts are modeling for continued growth. The target range implied by estimated revenue (low of $5.60B to high of $5.77B) and EPS (low of $14.22 to high of $14.78) is relatively tight, suggesting stronger conviction in the company's near-term financial trajectory rather than high uncertainty, though the wide gap between the 52-week high and low stock prices reflects significant market volatility and disagreement on long-term value.
Bulls vs Bears: VEEV Investment Factors
The investment debate for Veeva hinges on whether its severe price correction is a structural warning or a compelling entry point. Currently, the bear case has stronger near-term evidence, anchored by a 39% annual decline, growth deceleration, and significant technical damage. However, the bull case is supported by a fortress balance sheet, dominant market position, and a forward P/E that prices in substantial growth. The single most important tension is the resolution of its growth trajectory: if the company can re-accelerate revenue growth towards 20% and demonstrate path to its 2030 target, the current valuation will look attractive; if deceleration persists or margins erode further, the stock risks further de-rating.
Bullish
- Dominant Niche Market Position: Veeva is the global leader in cloud software for the highly regulated life sciences industry, a position built on deep domain expertise that displaces legacy systems. This entrenched market leadership provides a durable competitive moat and underpins its long-term revenue doubling target by 2030.
- Strong Profitability & Cash Generation: The company maintains exceptional profitability with a 74.46% gross margin and a 29.41% operating margin. It generates robust free cash flow of $1.39 billion TTM, funding growth internally and providing strategic flexibility without debt reliance, as evidenced by a negligible debt-to-equity ratio of 0.013.
- Compelling Forward Valuation: The stock's forward P/E of 17.08x represents a significant discount to its trailing P/E of 36.74x, indicating the market is pricing in substantial earnings growth. This forward multiple suggests the valuation has compressed to a more reasonable level after the 39% annual price decline.
- Healthy Revenue Growth Trajectory: Q4 revenue grew 15.96% year-over-year to $835.95 million, driven primarily by its Subscription Services segment ($644.63M). While showing signs of deceleration, this mid-teens growth in a stable industry supports the company's long-term expansion narrative.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 39.06% over the past year and 23.72% over six months, trading 45% below its 52-week high. Its relative strength of -58.20% vs. the S&P 500 indicates profound market skepticism about its growth story and valuation.
- Revenue Growth Deceleration: The most recent quarterly revenue growth of 15.96% YoY, while healthy, marks a sequential slowdown from prior quarters. This deceleration raises concerns about market saturation or competitive pressures in its core life sciences niche, challenging the long-term doubling target.
- Margin Compression & Elevated Valuation Multiples: The operating margin compressed from 32.15% in Q3 to 29.41% in Q4. Despite the price decline, valuation remains rich with a Price/Sales ratio of 10.44x and a trailing P/E of 36.74x, leaving the stock vulnerable to further multiple compression if growth falters.
- High Dependence on Single Industry: Veeva's entire business model is concentrated on the life sciences industry. This lack of diversification exposes it to sector-specific regulatory changes, R&D budget cycles, and consolidation among pharmaceutical clients, creating concentrated revenue risk.
VEEV Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price change of -39.06% and a 6-month decline of -23.72%. With a current price of $171.36, it is trading approximately 14% above its 52-week low of $148.05 but remains 45% below its 52-week high of $310.5, positioning it in the lower quartile of its annual range, which suggests the market is pricing in significant fundamental concerns rather than offering a clear value opportunity. Recent momentum shows a stark divergence, with a 1-month gain of 8.12% sharply contrasting the longer-term weakness, potentially signaling a technical rebound or dead-cat bounce within the broader downtrend; however, the 3-month performance remains negative at -0.71%, indicating the short-term uptick lacks conviction. Key technical support is firmly established at the 52-week low near $148, while major resistance sits at the 52-week high of $310.5; a sustained break below support could trigger another leg down, whereas reclaiming the $200 level would be a first step toward stabilizing the chart. The stock's beta of 0.949 indicates volatility roughly in line with the broader market, but its severe underperformance is highlighted by a relative strength of -58.20% over the past year.
Beta
0.95
0.95x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-38.4%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | +1.8% | -1.3% |
| 3m | +2.7% | +14.0% |
| 6m | -20.5% | +9.5% |
| 1y | -38.4% | +20.9% |
| ytd | -19.1% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue growth remains healthy but shows signs of sequential deceleration; the most recent quarterly revenue of $835.95 million grew 15.96% year-over-year, yet this marks a slowdown from the 16%+ YoY growth in prior quarters (e.g., Q3 revenue was $811.24 million). Segment data reveals the Subscription Services for Veeva Commercial Cloud, at $644.63 million, is the primary growth driver, vastly outweighing the $95.04 million from Professional Services. The company is highly profitable with robust margins, reporting net income of $244.20 million and a gross margin of 74.46% for the latest quarter; the operating margin of 29.41% is strong, though it has compressed slightly from 32.15% in the previous quarter, indicating potential pressure from investments or competitive dynamics. The balance sheet is exceptionally strong with minimal debt and ample liquidity, featuring a debt-to-equity ratio of only 0.013 and a current ratio of 4.89; the company generates substantial cash, with free cash flow over the trailing twelve months at $1.39 billion, providing significant internal funding capacity for growth initiatives and strategic flexibility without reliance on external financing.
Quarterly Revenue
$835951000.0B
2026-01
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given a positive net income of $244.20 million, the primary valuation metric is the P/E ratio. The trailing P/E stands at 36.74x, while the forward P/E is significantly lower at 17.08x, indicating the market expects substantial earnings growth in the coming year to justify the current price. Compared to sector averages, Veeva's trailing P/E of 36.74x and Price/Sales ratio of 10.44x likely command a premium, reflective of its superior growth profile, high profitability, and market leadership within the healthcare IT niche, though the exact industry comparison multiples are not provided in the data. Historically, the current trailing P/E of 36.74x is below the stock's own historical range seen in recent quarters, which has spanned from approximately 34x to over 115x, suggesting the valuation has compressed significantly from prior optimistic levels and may now be pricing in a more realistic growth trajectory or perceived risks.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 34x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Veeva's primary financial risk is not leverage or liquidity—its balance sheet is pristine with minimal debt and a 4.89 current ratio—but rather growth sustainability and margin pressure. Revenue growth decelerated to 15.96% YoY in Q4, and operating margin compressed nearly 300 basis points sequentially to 29.41%. The company's valuation (36.74x trailing P/E, 10.44x P/S) is entirely dependent on maintaining premium growth rates; any further slowdown could trigger significant multiple compression. Additionally, its revenue is concentrated in the life sciences industry, creating exposure to regulatory changes and client R&D budget cycles.
Market & Competitive Risks: The stock faces substantial valuation risk, trading at premium multiples despite its 39% decline. With a forward P/E of 17.08x, the market already expects strong earnings growth; failure to deliver could compress multiples toward sector averages. Competitive risks include potential disruption from larger enterprise software vendors or niche competitors. Macro risks are elevated given the stock's 0.95 beta and recent underperformance during market strength (relative strength -58.20%), indicating it's being treated as a discretionary growth stock rather than a defensive healthcare play. Recent news highlighting geopolitical uncertainty favoring defensive sectors poses a headwind.
Worst-Case Scenario: The worst-case scenario involves a combination of growth deceleration accelerating below 10%, margin compression due to increased competition or investment needs, and a broader market sell-off in high-multiple software stocks. This could trigger analyst downgrades and a re-rating toward value stock multiples. The realistic downside would see the stock testing and breaking its 52-week low of $148.05, representing a potential -14% decline from the current $171.36. In an extreme scenario mirroring its maximum drawdown of -50.55%, the stock could fall toward the $150-$160 range, resulting in a -10% to -15% loss from current levels.
FAQ
The primary risks are: 1) Growth sustainability: Revenue growth decelerated to 15.96% YoY; further slowdown could compress its premium valuation multiples. 2) Industry concentration: 100% exposure to life sciences creates regulatory and client budget dependency. 3) Valuation compression: With a trailing P/E of 36.74x and P/S of 10.44x, the stock remains vulnerable to sector rotation away from high-multiple names. 4) Technical damage: The stock is down 39% over the past year with -58% relative strength, indicating persistent selling pressure that could continue. Margin compression (operating margin fell from 32.15% to 29.41% QoQ) represents an emerging operational risk.
The 12-month forecast presents three scenarios: Bull case (30% probability, $240-$280) if growth re-accelerates above 18%; Base case (55% probability, $185-$220) if growth stabilizes at 15-16% meeting analyst estimates; Bear case (15% probability, $148-$170) if growth decelerates further. The base case is most likely, aligning with analyst revenue estimates of $5.69B and EPS of $14.50. The key assumption is that Veeva can maintain mid-teens growth without significant margin erosion, justifying its forward P/E of 17x. The stock likely trades in the $185-$220 range absent major catalysts.
VEEV is fairly valued to slightly overvalued relative to its current growth trajectory. The trailing P/E of 36.74x is rich, but the forward P/E of 17.08x suggests the market expects substantial earnings growth. The Price/Sales ratio of 10.44x commands a premium typical for best-of-breed software companies. Compared to its own history, the valuation has compressed significantly from prior highs. The market is paying a fair price for 15-16% growth with exceptional profitability, but any further growth deceleration would make the stock overvalued at current levels.
VEEV is a conditional buy for patient investors with a 2-3 year horizon. At a forward P/E of 17.08x, it offers reasonable valuation for a company with 15.96% growth, 74% gross margins, and a dominant market position. However, the 39% annual decline and growth deceleration create near-term risk. It's a good buy for investors who believe growth will stabilize or re-accelerate, but those seeking immediate returns should wait for technical improvement above $185. The biggest downside risk is further growth slowdown triggering additional multiple compression toward the 52-week low of $148.
VEEV is primarily suitable for long-term investment (3+ years). The company's value proposition—doubling revenue by 2030 as the dominant life sciences cloud platform—requires time to unfold. Short-term trading is challenged by the stock's 0.95 beta correlation with market volatility and severe technical overhead from the 39% decline. The lack of a dividend and focus on growth reinvestment further supports a long-term holding period. Investors should be prepared for continued volatility but can benefit from the company's strong fundamentals compounding over time. A minimum 18-24 month horizon is recommended to allow for growth stabilization and potential multiple expansion.